Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape

05-03-2019

NEW YORK, March 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Nektar Therapeutics (NASDAQ:NKTR), Workday, Inc. (NASDAQ:WDAY), Workiva Inc. (NYSE:WK), and MAG Silver Corporation (NYSE:MAG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CGC DOWNLOAD: https://Capital-Review.com/register/?so=CGC
AIMT DOWNLOAD: https://Capital-Review.com/register/?so=AIMT
NKTR DOWNLOAD: https://Capital-Review.com/register/?so=NKTR
WDAY DOWNLOAD: https://Capital-Review.com/register/?so=WDAY
WK DOWNLOAD: https://Capital-Review.com/register/?so=WK
MAG DOWNLOAD: https://Capital-Review.com/register/?so=MAG

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Canopy Growth Corporation (NYSE:CGC), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Nektar Therapeutics (NASDAQ:NKTR), Workday, Inc. (NASDAQ:WDAY), Workiva Inc. (NYSE:WK), and MAG Silver Corporation (NYSE:MAG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 1st, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CANOPY GROWTH CORPORATION (CGC) REPORT OVERVIEW

Canopy Growth's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Canopy Growth reported revenue of $62.79MM vs $40.47MM (up 55.16%) and analysts estimated basic earnings per share $0.17 vs $0.01 (up 2,005.06%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Canopy Growth reported revenue of $139.07MM vs $76.15MM (up 82.64%) and analysts estimated basic earnings per share -$0.31 vs -$0.11. Analysts expect earnings to be released on June 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.41 and is expected to report on June 26th, 2019.

To read the full Canopy Growth Corporation (CGC) report, download it here: https://Capital-Review.com/register/?so=CGC

-----------------------------------------

AIMMUNE THERAPEUTICS, INC. (AIMT) REPORT OVERVIEW

Aimmune Therapeutics' Recent Financial Performance

Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.92. The estimated EPS forecast for the next fiscal year is -$1.95 and is expected to report on February 27th, 2020.

To read the full Aimmune Therapeutics, Inc. (AIMT) report, download it here: https://Capital-Review.com/register/?so=AIMT

-----------------------------------------

NEKTAR THERAPEUTICS (NKTR) REPORT OVERVIEW

Nektar Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Nektar Therapeutics reported revenue of $27.76MM vs $152.93MM (down 81.85%) and analysts estimated basic earnings per share -$0.56 vs $0.39. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Nektar Therapeutics reported revenue of $307.71MM vs $165.44MM (up 86.00%) and analysts estimated basic earnings per share -$0.62 vs -$1.10. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.60. The estimated EPS forecast for the next fiscal year is -$2.41 and is expected to report on February 27th, 2020.

To read the full Nektar Therapeutics (NKTR) report, download it here: https://Capital-Review.com/register/?so=NKTR

-----------------------------------------

WORKDAY, INC. (WDAY) REPORT OVERVIEW

Workday's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Workday reported revenue of $743.19MM vs $555.39MM (up 33.81%) and basic earnings per share -$0.70 vs -$0.41. For the twelve months ended January 31st, 2018 vs January 31st, 2017, Workday reported revenue of $2,143.05MM vs $1,574.44MM (up 36.12%) and analysts estimated basic earnings per share -$1.55 vs -$1.94. Analysts expect earnings to be released on May 30th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$0.96 and is expected to report on February 27th, 2020.

To read the full Workday, Inc. (WDAY) report, download it here: https://Capital-Review.com/register/?so=WDAY

-----------------------------------------

WORKIVA INC. (WK) REPORT OVERVIEW

Workiva's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Workiva reported revenue of $64.44MM vs $54.51MM (up 18.22%) and analysts estimated basic earnings per share -$0.18 vs -$0.34. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Workiva reported revenue of $244.34MM vs $207.87MM (up 17.55%) and analysts estimated basic earnings per share -$1.15 vs -$1.07. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is -$0.92 and is expected to report on February 19th, 2020.

To read the full Workiva Inc. (WK) report, download it here: https://Capital-Review.com/register/?so=WK

-----------------------------------------

MAG SILVER CORPORATION (MAG) REPORT OVERVIEW

MAG Silver's Recent Financial Performance

Analysts expect earnings to be released on March 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.05. The estimated EPS forecast for the next fiscal year is -$0.06 and is expected to report on March 25th, 2019.

To read the full MAG Silver Corporation (MAG) report, download it here: https://Capital-Review.com/register/?so=MAG

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Latest news
Related news
Related shares
Nektar Therapeutics
VOL 445,734
32.14 USD
-0.36 / -1.09 %

Workday Inc.
VOL 545,701
217.81 USD
4.31 / 2.02 %

Workiva Inc Class A
VOL 30,084
59.16 USD
0.43 / 0.73 %